Zacks Rating on Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Industries Limited (TEVA) : The consensus on Teva Pharmaceutical Industries Limited (TEVA) based on 17 analyst recommendation on the company stock is 1.68, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 10 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Teva Pharmaceutical Industries Limited (TEVA) : Average target price received by Teva Pharmaceutical Industries Limited (TEVA) is $73.39 with an expected standard deviation of $10.05. The most aggressive target on the stock is $100, whereas the most downbeat target is $57. 15 financial analysts are currently covering the stock.


Teva Pharmaceutical Industries Limited has lost 0.46% in the last five trading days and dropped 1.45% in the last 4 weeks. Teva Pharmaceutical Industries Limited is up 3.19% in the last 3-month period. Year-to-Date the stock performance stands at -17.39%. Teva Pharmaceutical Industries Limited (NYSE:TEVA): On Tuesdays trading session , Opening price of the stock was $53.45 with an intraday high of $53.835. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $53.11. However, the stock managed to close at $53.2, a loss of 0.52% for the day. On the previous day, the stock had closed at $53.48. The total traded volume of the day was 3,437,298 shares.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.